Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Inflammation and the immune system

Topic: Brain proteins, microglia and lab models

Cerebral small vessel disease (CSVD) is a chronic, progressive cerebrovascular disorder affecting small arteries, arterioles, venules, and capillaries, and is a leading contributor to stroke, vascular dementia, and cognitive impairment. Accumulating evidence has revealed that the pathogenesis of CSVD is multifactorial, with neuroinflammation and blood-brain barrier (BBB) dysfunction emerging as central pathological processes. Notably, a bidirectional feedback loop between neuroinflammation and BBB breakdown has been identified. Endothelial cells, microglia, oligodendrocytes, as main cell components in maintaining the physiological functions of BBB performed significant roles. Imaging modalities have improved detection of BBB permeability changes and CSVD progression. Recent translational research has identified potential biomarkers for early diagnosis. Therefore, some new therapeutic approaches targeting the neuroinflammation-BBB axis can provide better early intervention for CSVD and have superior therapeutic effects. In our review, we first elaborated on the pathological role of CSVD, particularly emphasizing the importance of the integrity of the BBB. Then, we highlighted the clinical characteristics and translational research evidence of CSVD, including novel imaging and biochemical biomarkers, potential therapeutic approaches, and the progress of preclinical models, thereby revealing the research progress of CSVD.

Key findings

Why it matters

This review describes neuroinflammation and blood-brain barrier dysfunction as central processes in cerebral small vessel disease, a contributor to vascular dementia, and discusses potential biomarkers and therapies targeting this axis. No treatment is proven here, and the work is a review of mechanisms and early translational research.

Study details

How this study scored 45/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 43 of the 96 points it could be judged on, which is 45 of 100. Total 45 of 100.43 of the 96 points we could judge = 45 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 43 of the 96 points we could judge it on, which is 45 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (European journal of medical research)
Journal's citation record 1 / 4 European journal of medical research: journal h-index 80 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 18 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 9.0 citations a year over 2 year(s) since 2026
Impact for its field and year 6 / 6 Cited 45.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Song Qiao holds only 3 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Zhejiang Chinese Medical University: institution h-index 228 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41578396)
Free to read 2 / 2 Free to read
Points 43 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 96 points we could judge it on is 45 out of 100.
Total 45 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Luo, L., & Qiao, S. (2026). Neuroinflammation and blood–brain barrier dysfunction in cerebral small vessel disease: mechanisms, biomarkers, and therapeutic implications. European journal of medical research. https://doi.org/10.1186/s40001-026-03840-z

Vancouver

Luo L, Qiao S. Neuroinflammation and blood–brain barrier dysfunction in cerebral small vessel disease: mechanisms, biomarkers, and therapeutic implications. European journal of medical research. 2026. doi:10.1186/s40001-026-03840-z. PMID: 41578396.

BibTeX

@article{luo2026-41578396,
  author  = {Luo, Lixin and Qiao, Song},
  title   = {{Neuroinflammation and blood–brain barrier dysfunction in cerebral small vessel disease: mechanisms, biomarkers, and therapeutic implications}},
  journal = {European journal of medical research},
  year    = {2026},
  doi     = {10.1186/s40001-026-03840-z},
  pmid    = {41578396},
  url     = {https://doi.org/10.1186/s40001-026-03840-z}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.

Related studies in Inflammation and the immune system

Also tagged “cerebral”

900 studies in the library carry the topic tag “cerebral”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →